Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480169 | 0.85 | PTPN1 (0.62) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL28515929 | 0.85 | PTPN1 (0.62) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL28073989 | 0.85 | PTPN1 (0.62) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27649591 | 0.85 | PTPN1 (0.62) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27357388 | 0.82 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27370153 | 0.82 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL27369404 | 0.82 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL5720401 | 0.82 | PTPN1 (0.59) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL6242035 | 0.80 | PTPN1 (0.56) | PTPN1LMNAPTGS1PDE4ASNCA | |
| SCHEMBL6242039 | 0.80 | PTPN1 (0.56) | PTPN1LMNAPTGS1PDE4ASNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189258-A1 | CANCER CELL GROWTH INHIBITING COMPOSITION AND PROCESSED FOOD | Hagihara Farm Production Institute Co., Ltd. (JP) | 2024-06-13 | — | — | US | disclosed |
| CN-117440806-A | Cancer cell proliferation inhibiting composition and processed food | 株式会社萩原农场生产研究所 | 2024-01-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189258-A1 | CANCER CELL GROWTH INHIBITING COMPOSITION AND PROCESSED FOOD | MKI67, CCNT1, CCNI | PTPN1 858/4885LMNA 1838/4885PTGS1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.